Cipher Pharmaceuticals Inc. (CPHRF) Stock Price & Analysis
Cipher Pharmaceuticals Inc. (CPHRF) — price $9.05 (-0.11%), as of the Nov 20, 2026 trading session; market cap $230M.
Educational signal · not a buy or sell recommendation · How to read this
Cipher Pharmaceuticals Inc. · CPHRF
Cipher Pharmaceuticals Inc. is a Canadian specialty pharmaceutical company focused on acquiring, developing, and commercializing a portfolio of prescription products across various therapeutic areas. The company manages both commercialized and licensed products, alongside a pipeline of development-stage candidates targeting conditions like severe acne, hyperlipidemia, and pulmonary arterial hypertension.
Price as of Nov 20, 2026
Key Statistics
No MoonshotScore yet: we have not published a score for this company.
Price & valuation
| Measure | Value |
|---|---|
| Latest provided price | $9.05 |
| Change on the day | -0.11% |
| Market capitalisation | $230M |
| Price / earnings (trailing) | 6.74 |
| Shares traded on the day | 1.7K |
Price & events
Other perspectives
Council score for Cipher Pharmaceuticals (CPHRF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
3 lenses, 3 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 22, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 20, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
The Munger lens reads the current price as undervalued against its own estimate of value.
Readings on this page are from Nov 22, 2026, except a card that shows its own read date.
What is Cipher Pharmaceuticals (CPHRF), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Cipher Pharmaceuticals Inc. (CPHRF) is the company analyzed here. In Q3 FY2025 it reported revenue of $13M and net income of $6M. The market values it at $230M.
What do the latest results show for Cipher Pharmaceuticals (CPHRF)?
Short answer · as of
The most recent reported quarter, Q3 FY2025, carried revenue of $13M. Against analyst estimates the company has EPS beat 1 of the last 4 reports.
Quarterly income statement — 3 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2025 | $13M | $6M | $0.21 (diluted) |
| Q4 FY2025 | $12M | $13M | — |
| Q1 FY2026 | $13M | $6M | $0.24 (diluted) |
What are the financial strengths and risks for Cipher Pharmaceuticals (CPHRF)?
Short answer
The distress and quality screens read Altman Z 8.09 · Piotroski F 5. Trailing ratios: ROE 26.4% · ROA 9.6% · current ratio 1.99.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held CPHRF in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported CPHRF in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Cipher Pharmaceuticals (CPHRF)?
What Investors Ask About Cipher Pharmaceuticals (CPHRF)
These answers are editorial: 1 of these 8 answers is drawn from the CPHRF research dossier (written Jun 15, 2026 by gemini-2.5-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is CPHRF a good stock to buy?
Stock Expert AI does not rate CPHRF buy, sell or hold. Cipher Pharmaceuticals Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the CPHRF stock price today?
The last price recorded for Cipher Pharmaceuticals Inc. (CPHRF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the implications of Cipher Pharmaceuticals Inc. trading on the OTC market for investors?
Cipher Pharmaceuticals Inc.'s trading on the OTC Other tier of the OTC market carries several implications for investors. Unlike major exchanges, the OTC Other tier has minimal disclosure requirements, leading to an "Unknown" disclosure status for Cipher, which means less readily available financial and operational information. This can complicate thorough due diligence.
What are the key factors to evaluate for CPHRF?
Evaluate CPHRF on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. PAH is a serious, progressive disease with a need for effective treatments. Not financial advice.
How frequently does CPHRF data refresh on this page?
CPHRF's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven CPHRF's recent stock price performance?
Cipher Pharmaceuticals Inc. (CPHRF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse portfolio of commercial and licensed specialty pharmaceutical products. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CPHRF overvalued or undervalued right now?
The trailing P/E of Cipher Pharmaceuticals Inc. (CPHRF) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research CPHRF before investing?
Before investing in Cipher Pharmaceuticals Inc. (CPHRF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 12 figures on this page — 10 from Financial Modeling Prep (FMP) and 2 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com